BCAN antisense RNA 2 (BCAN-AS2)

BCAN antisense RNA 2 (BCAN-AS2) is a long non-coding RNA (lncRNA) annotated as an antisense RNA—meaning it is transcribed from the DNA strand opposite to the BCAN (Brevican) gene and may play regulatory roles through RNA-RNA interactions with the sense (BCAN) transcript or other targets[2][3][4]. BCAN-AS2 is implicated in processes such as epithelial barrier maintenance and neural lineage regulation, though its specific physiological or pathological roles are not well characterized[3]. As with other antisense RNAs, BCAN-AS2 is believed to function generally by regulating gene expression at transcriptional or post-transcriptional levels, but there is no evidence that it acts as a therapeutic target, is directly involved in common disease etiologies, or interacts with approved drugs[2][3][4]. Note: - There is no indication that BCAN-AS2 is a receptor, enzyme, transporter, or conventional therapeutic target protein. - The alias ENST869 appears twice but refers to the same transcript; AL590666.2 is an Ensembl transcript ID for this lncRNA. - Current sources do not associate BCAN-AS2 with known drugs, mechanisms of action, disease biomarkers, or specific safety concerns. - Its functional and disease associations are limited to general non-coding RNA regulatory activity, not direct involvement in cancer, inflammation, or other major disease classes at this time[3][4].

Other names

ENST869AL590666.2BCAN-AS2